preview

Case Study Of Pneumonia

Satisfactory Essays

This article presented a non-experimental level four study. The reason for this study was to compare different SUP therapy such as PPIs and H2 antagonists, which increase gastric acid pH as opposed to sucralfate which does not raise pH, and whether they increase the rates of ventilator associated pneumonia (VAP). The thought is that SUP that increased gastric pH such as PPIs and H2 antagonists might contribute to the development of VAP. The independent variables in this study are PPIs, H2 receptor antagonists and sucralfate. The dependent variable is VAP rates. The type of data collected in this study was nominal, interval, and ratio. The authors concluded that sucralfate therapy should be favored over PPI and H2 antagonists in intubated …show more content…

The nominal data collected was SUP type, gender, APACHE II, and trauma. Ratio data collected was age and ICU LOS. Interval data was days on mechanical ventilation. Statistical analyses included descriptive measures as well as inferential measures such as Fisher’s exact tests and t-tests which compared patient characteristics. The MMC Institutional Review Board for Human Subjects approved this study. However, the IRB waived the informed consent requirement since this study was a retrospective chart review. Level of significance was p < 0.01. Results. The researchers found a significant relationship between HAI rates and SUP with PPI/H2 blockers or sucralfate (p < 0.01). A total of 45 VAP occurrences developed in both SUP groups, which met CDC criteria, in both the PPI/H2 blocker group and sucralfate group. Twelve of the patients treated with sucralfate developed VAP and 33 of the patients treated with PPI/H2 blockers developed VAP. Discussion. Overall, researchers found a significant difference in the VAP occurrence within the group treated with sucralfate and the group treated with PPI/H2 blockers. One limitation of this study is that the PPI/H2 blocker group was larger than the sucralfate group, there was 286 patients in the PPI/H2 blocker group and only 172 patients in the sucralfate group. This may be a limitation because the incidence of VAP rates was not equally studied between the PPI/H2 blocker group and the sucralfate group. Having less patients in the

Get Access